BriaCell Therapeutics Corp. (TSE:BCT) Forecasted to Earn Q3 2024 Earnings of ($0.75) Per Share

BriaCell Therapeutics Corp. (TSE:BCT) – HC Wainwright lowered their Q3 2024 EPS estimates for shares of BriaCell Therapeutics in a note issued to investors on Tuesday, April 9th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.75) per share for the quarter, down from their prior forecast of ($0.28). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.62) EPS, FY2024 earnings at ($1.89) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($2.23) EPS, FY2027 earnings at ($1.97) EPS and FY2028 earnings at ($1.51) EPS.

BriaCell Therapeutics (TSE:BCT) last posted its earnings results on Monday, March 18th. The company reported C($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.28) by C($0.68).

BriaCell Therapeutics Stock Down 8.4 %

Shares of TSE:BCT opened at C$3.40 on Friday. The firm’s 50 day moving average price is C$4.21 and its 200-day moving average price is C$5.66. BriaCell Therapeutics has a twelve month low of C$3.00 and a twelve month high of C$10.29. The stock has a market capitalization of C$54.33 million, a PE ratio of -3.18 and a beta of 1.74.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.